For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
The PERRFECT Study - A phase 2 clinical trial evaluating use of the NeuroPoint medical device as a treatment for fibromyalgia.
Fibromyalgia
Location of study visits: Ann Arbor, MI
In this study, we are testing a type of therapy called Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE). RINCE involves using a special device (NeuroPoint) to electrically stimulate the brain. We want to find out how well RINCE works in treating people with fibromyalgia.
This study is looking for: female  Only women
  • Volunteers with specific conditions
  • 18 years to 65 years
In this study, we are testing a type of therapy called Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE). RINCE involves using a special device (NeuroPoint) to electrically stimulate the brain. We want to find out how well RINCE works in treating people with fibromyalgia.
45 HEROES have already shown interest in this study. I am interested Print Study | Email Study
Who can participate?
What is involved? The study involves 35 visits over an 18 week period. This includes 1 screening visit, 32 stimulation treatments of 30 minutes in duration, and 3 all-day research evaluations which include pressure-pain testing, EEG, and 90 minute fMRI brain scans. We are recruiting participants with a Fibromyalgia diagnosis who experience chronic, widespread pain.
Compensation Participants will receive compensation for their participation (up to $1715).
More about the study
Participants must be able to undergo treatment visits twice weekly for the duration of the study, in addition to spending three 5-6 hour days involved in research evaluations. All visits will occur on weekdays during business hours. Eligibility for this study also requires that you are between 18 and 65 years old, are right-handed, and are willing to modify your use of certain medications and adjunct therapies that you may be using to treat your fibromyalgia symptoms during participation in the study. You must not begin any new therapies during the course of the treatment phase of this study. You must not be pregnant and be willing to take measures to prevent becoming pregnant during the study. Participants must also be willing to complete all of the study's therapy visits and meet the requirements for having an fMRI scan.

IRB number: HUM00071597
Activation Date: 09/04/2013    Deactivation Date: 12/31/2014
Study Team Principal Investigator:  Clauw, Daniel J Department:  Anesthesiology
Study Contact: Megan Halvorson
(734) 998-6839
meganeb@med.umich.edu
We respect your privacy! UMClinicalStudies.org is a secure, password-protected database. All the information that you choose to share will be kept private and confidential. Read University of Michigan's Notice of Privacy Practices.